Dan Kemp, Wugen CEO

A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and be­yond

The promise of next-gen, “off-the-shelf” cell ther­a­pies have thor­ough­ly en­tranced bio­phar­ma with the promise of low­er­ing man­u­fac­tur­ing costs and po­ten­tial­ly chal­leng­ing dom­i­nant check­point in­hibitors. But to get there, com­pa­nies need a po­tent ther­a­py and one that can be con­tin­u­ous­ly sourced from donors.

A new biotech un­cloak­ing from a lengthy de­vel­op­ment pe­ri­od thinks it may have solved that puz­zle.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.